First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study

被引：0
|
作者：
Andreis, D.
Scandurra, G.
Santini, D.
Gucciardino, C.
La Verde, N. M.
Girelli, S.
Alabiso, I.
Saetta, A.
Atzori, F.
Collova, E.
Ferzi, A.
Gori, S.
Lipari, H.
Saggia, C.
Marcon, I.
Generali, D. G.
机构：
[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy
[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy
[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy
[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy
[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy
[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy
[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[8] Osped Civile Legnano, Legnano, Italy
[9] AO Perugia, Oncol Med, Perugia, Italy
[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy
[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy
[12] AO Osped Circolo, UO Oncol, Varese, Italy
[13] Fdn Macchi, Varese, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11502
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer
    Puglisi, Fabio
    Bisagni, Giancarlo
    Ciccarese, Mariangela
    Fontanella, Caterina
    Gamucci, Teresa
    Leo, Luigi
    Molino, Annamaria
    Silva, Rosa Rita
    Marchetti, Paolo
    FUTURE ONCOLOGY, 2016, 12 (22) : 2589 - 2602
  • [42] MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer
    Miles, David
    Faoro, Leonardo
    Wang, Yan V.
    O'Shaughnerary, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Choice of primary endpoints in first-line phase III trials of HER2-negative or HER2-unknown metastatic breast cancer (MBC).
    Kuemmel, Sherko
    Mueller, Volkmar
    Lux, Michael P.
    Weyer, Geerd
    Pintoffl, Jan P.
    Jackisch, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
    Dieras, Veronique
    Wildiers, Hans
    Jassem, Jacek
    Dirix, Luc Y.
    Guastalla, Jean-Paul
    Bono, Petri
    Hurvitz, Sara A.
    Goncalves, Anthony
    Romieu, Gilles
    Limentani, Steven A.
    Jerusalem, Guy
    Lakshmaiah, K. C.
    Roche, Henri
    Sanchez-Rovira, Pedro
    Pienkowski, Tadeusz
    Segui Palmer, Miguel Angel
    Li, Ai
    Sun, Yu-Nien
    Pickett, Cheryl A.
    Slamon, Dennis J.
    BREAST, 2015, 24 (03): : 182 - 190
  • [45] Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer
    Yamashiro, H.
    Yamamoto, Y.
    Schneeweiss, A.
    Mueller, V.
    Gluz, O.
    Klare, P.
    Aktas, B.
    Magdolna, D.
    Buedi, L.
    Piko, B.
    Mangel, L.
    Toi, M.
    Morita, S.
    Ohno, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S367 - S367
  • [46] Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons
    Sini, Valentina
    Cassano, Alessandra
    Corsi, Domenico
    De Laurentiis, Michele
    Gamucci, Teresa
    Mauri, Mariella
    Naso, Giuseppe
    Roselli, Mario
    Ruggeri, Enzo Maria
    Tonini, Giuseppe
    Vici, Patrizia
    Zampa, Germano
    Marchetti, Paolo
    TUMORI JOURNAL, 2016, 102 (05): : 472 - 480
  • [47] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).
    O'Shaughnessy, Joyce
    Young, Robyn R.
    Levin, Maren K.
    Baisch, Jeanine
    Timis, Roxana
    Muniz, Luz Stella
    Turner, Jacob
    Pascual, Virginia
    Palucka, Karolina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC)
    Borson, R.
    Harker, W. G.
    Reeves, J. E.
    Drosick, D.
    Beck, J. T.
    Hager, S. J.
    Horvath, W. L.
    Bromund, J.
    Zeigler, H.
    Tai, D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study
    Manso, Luis
    Garcia Palomo, Andres
    Perez Carrion, Ramon
    Cassinello, Javier
    Gallegos Sancho, Isabel
    Chacon Lopez-Muniz, Ignacio
    Olier, Clara
    Fernandez-Aramburo, Antonio
    Llorca, Cristina
    Gonzalez, Xavier
    Llorente, Rosa
    Torregrosa, Dolores
    Alvarez, Inaki
    Galve, Elena
    Bueno, Coralia
    Garau, Isabel
    Garcia, Maria Jose
    Gonzalez-Santiago, Santiago
    Ballesteros, Ana Isabel
    Blanco, Esperanza
    Galan, Antonio
    Gonzalez, Sonia
    Perello, Antonia
    Cortes-Funes, Hernan
    Gravalos, Cristina
    ANTICANCER RESEARCH, 2015, 35 (12) : 6941 - 6950
  • [50] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
    Ni, M.
    Zhou, L.
    Lu, Y.
    Zhang, L.
    Li, X.
    Chen, M.
    Yang, A.
    Zhang, L.
    Xu, F.
    Yuan, Z.
    Wang, S.
    Shi, Y.
    An, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1490 - S1490
12345